FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
16/08/2022
Voltar para busca
Dado oficial do USPTO
PEREGRINE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
PEREGRINE
ST13
US500000079303095Classe
5, 42, 44
Pedido
79303095
Registro
6641521
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
26
Atualização mais recente
16/08/2022
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42, 44
Data de depósito
26/10/2020
Data de registro
15/02/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
15/02/2022
Última transação
15/02/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
78
Localização do titular
NL
Examinador
RUTLAND, BARBARA
Unidade examinadora
L10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
SkylineDx B.V.
Representantes
James C. Watson TraskBritt, P.C.
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medical molecular diagnostic test reagents; medical molecular diagnostic test reagents of body substancessuch as bone marrow samplesblood sampleson human or animal tissue; molecular diagnostic test reagents for cancer for medical purposes; medical molecular diagnostic test reagentsinter alia on the basis of microarray technology and sequencing technology; reagents for use in medical genetic testing; reagents for use in medical genetic testing for the measurement of the gene expression profile; reagents for use in medical genetic testing for the measurement of gene aberrations and mutations; clinical diagnostic test reagents for determination of genetic sub-type of a patient; medical prognostic test reagents for testing of bodily fluids for use in disease detectionnamely oncology; predictive test reagentsin search of the effectiveness of a medical treatment and/or to select the medical treatment; diagnostic test reagents and preparations for medical or veterinary purposes; chemical preparationsfor medical purposesfor the testing of blood and human or animal tissueincluding cancer cells; medical diagnostic test strips for tissue-based diagnostics; diagnostic testing materials for medical usenamely oncology; preparations for detecting mutation in human genes for medical purposes
Classe 42
Research and development of new products for others; biochemical research and development; pharmaceutical research and development; research and development in the field of diagnostic preparations; biological researchclinical research provided via a website and medical research; scientific research for the benefit of the development of molecular diagnostic tests; analysis and evaluation of results from quality control tests of the goods of others to determine conformity with certification standards; molecular diagnostic analysis; investigation and analysis of body substances and molecular diagnostic test scores for the purpose of the development of new biomarkers development and diagnostic testing of treatment methods for scientific research for medical purposes; development and testing services for the certification of quality or standards of molecular diagnostic tests; computer aided diagnostic testing services for others in the field of science and research related thereto; scientific research for medical purposes in the area of cancerous diseases; genetic testing for scientific research purposes; research of pharmaceutical preparations in the field of gene therapy; providing information about medical research in the field of diagnostic testing services in the field of skin cancer
Classe 44
Medical analysis services for diagnostic and treatment-decision purposes provided by medical laboratories; medical analysis for diagnostic and treatment-decision purposes provided by medical laboratories using test scores and data for medical or veterinary purposes for others; medical and veterinary information services provided via the internet; medical testing for diagnostic or treatment purposes; medical diagnostic testingmonitoring and reporting services; medical analysis services for cancer diagnosis and prognosis; medical services for the treatment of skin cancer; medical analysis services for the diagnosis of cancer
Publicações
Histórico de despachos e eventos da marca no USPTO.
26 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
22/07/2022
FIMP
FINAL DISPOSITION PROCESSED
22/07/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
15/05/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
15/02/2022
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
02/01/2022
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
23/09/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
24/08/2021
PUBO
PUBLISHED FOR OPPOSITION
24/08/2021
GPNX
NOTIFICATION PROCESSED BY IB
22/08/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/08/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/08/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/08/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
16/07/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/07/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/07/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/07/2021
RFNT
REFUSAL PROCESSED BY IB
25/04/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/04/2021
RFRR
REFUSAL PROCESSED BY MPU
08/04/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/04/2021
CNRT
NON-FINAL ACTION WRITTEN
31/03/2021
DOCK
ASSIGNED TO EXAMINER
26/03/2021
MAFR
APPLICATION FILING RECEIPT MAILED
02/02/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
29/01/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
28/01/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PEREGRINE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.